The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

Background:This phase Ib trial assessed safety, tolerability, and maximum tolerated dose (MTD) of figitumumab (CP-751,871), a fully human monoclonal antibody targeting the insulin-like growth factor type 1 receptor (IGF-IR), in combination with docetaxel.Methods:Patients with advanced solid tumours were treated with escalating dose levels of figitumumab plus 75 mg m–2 docetaxel every 21 days. Safety, efficacy, pharmacokinetics (PKs), and biomarker responses were evaluated.Results:In 46 patients, no dose-limiting toxicities were attributable to the treatment combination. Grade 3 and 4 toxicities included neutropaenia (n=28), febrile neutropaenia (n=11), fatigue (n=10), leukopaenia (n=7), diarrhoea (n=5), hyperglycaemia, lymphopaenia, cellulitis, DVT, and pain (all n=1). The MTD was not reached. Four partial responses were observed; 12 patients had disease stabilisation of ⩾6 months. Pharmacokinetic and biomarker analyses showed a dose-dependent increase in plasma exposure, and complete sIGF-IR downregulation at doses of ⩾3 mg kg–1. Pharmacokinetics of docetaxel in combination was similar to when given alone. Out of 18 castration-resistant prostate cancer patients, 10 (56%) had ⩾5 circulating tumour cells (CTCs) per 7.5 ml of blood at baseline: 6 out of 10 (60%) had a decline from ⩾5 to <5 CTCs and 9 out of 10 (90%) had a ⩾30% decline in CTCs after therapy.Conclusions:Figitumumab and docetaxel in combination are well tolerated. Further evaluation is warranted.

• Publication year

  2010

• Venue

  British Journal of Cancer

• Publication date

  2010-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bjc.6605767PMID 20628389PMCID 2920021
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

  2009cited by this paper
• Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor

  2009cited by this paper
• Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

  2009cited by this paper
• Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.

  2009cited by this paper
• Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

  2008cited by this paper
• A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G)

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

  2008cited by this paper
• Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.

  2008cited by this paper
• Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

  2008cited by this paper
• A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)

  2008cited by this paper
• A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

  2008cited by this paper
• Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

  2007cited by this paper
• Oncologist communication about emotion during visits with patients with advanced cancer.

  2007cited by this paper
• Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

  2007cited by this paper
• The role of the IGF system in cancer growth and metastasis: overview and recent insights.

  2007cited by this paper
• A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors

  2007cited by this paper
• Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients

  2007cited by this paper
• IGF-I mediated survival pathways in normal and malignant cells.

  2006cited by this paper
• Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia.

  2006cited by this paper
• Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871

  2005cited by this paper
• The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge

  2005cited by this paper
• Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity

  2005cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004cited by this paper
• Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.

  2003cited by this paper
• Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin‐like growth factor receptor

  2003cited by this paper
• Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.

  2002cited by this paper
• Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.

  2002cited by this paper
• Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.

  2001cited by this paper
• Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.

  1998cited by this paper
• Noncompartmental Analysis Based on Statistical Moment Theory

  1982influential reference

• The Interplay Between Esophageal Adenocarcinoma and Its Tumor Microenvironment: Toward Innovative Therapies

  2025cites this paper
• Whole genome profiling of rare pediatric thoracic tumors elucidates a YAP1::LEUTX fusion in an unclassified biphasic embryonal neoplasm.

  2024cites this paper
• Insulin-like growth factor family and prostate cancer: new insights and emerging opportunities

  2024cites this paper
• Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies

  2023cites this paper
• The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities

  2023cites this paper
• Molecular aspects of Ewing's sarcomas

  2022cites this paper
• Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.

  2022cites this paper
• The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives

  2020cites this paper
• Role of the GH-IGF1 system in progression of cancer.

  2020cites this paper
• The role of insulin-like growth factors in the development of prostate cancer

  2020cites this paper
• Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

  2019cites this paper
• Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection.

  2019cites this paper
• Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy

  2019cites this paper
• Molecular Signaling in Tumorigenesis of Gastric Cancer

  2018cites this paper
• A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

  2018cites this paper
• Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome

  2018cites this paper
• Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

  2017cites this paper
• Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

  2017cites this paper
• Combination therapy in combating cancer

  2017cites this paper
• The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.

  2017cites this paper
• Clinical Implications of Molecular Heterogeneity of Gastric Cancer

  2017cites this paper
• Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study.

  2016cites this paper
• Risk of prostate cancer‐specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence

  2016cites this paper
• The role of insulin-like growth factor axis in bladder cancer : a systemic review and meta analysis

  2016cites this paper
• Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies

  2016cites this paper
• Type I insulin-like growth factor receptor signaling in hematological malignancies

  2016cites this paper
• Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy.

  2015cites this paper
• Biology of Ewing sarcoma

  2015cites this paper
• TARGETED INHIBITION OF PI3K, MTOR, AND IGF1R FOR THE TREATMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

  2015cites this paper
• Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

  2015influential citation
• Gastric cancer: The times they are a-changin'.

  2015cites this paper
• ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents

  2015cites this paper
• Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

  2015cites this paper
• Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions

  2015cites this paper
• Targeted Therapies for Prostate Cancer

  2015cites this paper
• Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

  2015cites this paper
• Management of advanced or recurrent cervical cancer: chemotherapy and beyond

  2014cites this paper
• Can we unlock the potential of IGF-1R inhibition in cancer therapy?

  2014cites this paper
• The effects of insulin-like growth factor 1 and growth hormone on human meibomian gland epithelial cells.

  2014cites this paper
• Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.

  2014cites this paper
• Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

  2014cites this paper
• Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

  2014cites this paper
• The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

  2014cites this paper
• Targeting receptor tyrosine kinases in gastric cancer.

  2014cites this paper
• Role of the tumor microenvironment in the pathogenesis of gastric carcinoma.

  2014cites this paper
• The role of FAK in tumor metabolism and therapy.

  2014cites this paper
• The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches

  2014cites this paper
• Recent advances and future trends in the targeted therapy of metastatic gastric cancer

  2014cites this paper
• Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

  2014cites this paper
• The synergistic effect of humanized monoclonal antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) and chemotherapy.

  2014cites this paper
• The adverse events profile of anti‐IGF‐1R monoclonal antibodies in cancer therapy

  2014cites this paper
• Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

  2013cites this paper
• Caloric restriction augments radiation efficacy in breast cancer

  2013cites this paper
• Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer

  2013cites this paper
• A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal

  2013cites this paper
• IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination

  2013cites this paper
• Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

  2013cites this paper
• IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease.

  2013cites this paper
• Targeting the insulin-like growth factor-1 receptor in human cancer

  2013cites this paper
• Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer

  2013influential citation
• Prerequisite Genetic Traits for Metastasis

  2013cites this paper
• Rational Categorization of the Pipeline of New Treatments for Advanced Cancer – Prostate Cancer as an Example

  2013cites this paper
• Targeting IGF-1 signaling pathways in gynecologic malignancies

  2013cites this paper
• Pharmacokinetics and Pharmacodynamics of Figitumumab, a Monoclonal Antibody Targeting the Insulin‐Like Growth Factor 1 Receptor, in Healthy Participants

  2013cites this paper
• Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.

  2012cites this paper
• Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors

  2012cites this paper
• Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

  2012cites this paper
• Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer

  2012cites this paper
• Novel molecular targets for the therapy of castration-resistant prostate cancer.

  2012cites this paper
• Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  2012cites this paper
• Insulin-like growth factor: current concepts and new developments in cancer therapy.

  2012cites this paper
• The Role of Insulin-Like Growth Factor Signaling in Prostate Cancer Development and Progression

  2012cites this paper
• Targeting IGF-1R: throwing out the baby with the bathwater?

  2011cites this paper
• Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.

  2011cites this paper
• The changing therapeutic landscape of castration-resistant prostate cancer

  2011cites this paper
• Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target?

  2011cites this paper
• Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer

  2011cites this paper
• Cancer Therapy : Preclinical The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of kras Mutation Status

  2011cites this paper
• Development of novel targeted agents in the treatment of metastatic colorectal cancer.

  2011cites this paper
• Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

  2011cites this paper
• Evaluation of two ELISA methods to detect therapeutic anti-IGF1R antibodies in clinical study samples of dalotuzumab.

  2011cites this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cites this paper
• Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells.

  2011cites this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cites this paper
• The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status

  2011cites this paper
• Insulin-Like Growth Factor Pathway–Targeted Therapy in Breast Cancer

  2011cites this paper
• Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer

  2011cites this paper
• Future directions in castrate-resistant prostate cancer therapy.

  2010cites this paper